Survival analyses in the validation cohort confirmed a significant association between shorter OS and B-cell-high status in RCC patients as shown in Fig. 2b (p-value = 0.034; Log-Rank-test), and an increased risk of death in the CD20-high group as determined by uni-variable Cox Regression analysis (HR = 1.9; 95% CI = 1.0–3.6; p-value = 0.039). The gene discussed is MS4A1; the disease is renal cell adenocarcinoma.